A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 5, 1996, Pages 429-434

  Ghazal Aswad, Saad ^a   Calvert, A Hilary ^a   Newell, David R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

AUC; AUC estimation; Carboplatin; Limited sampling strategy; Pharmacokinetics; Single sample assay

Indexed keywords

CARBOPLATIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM; PROSPECTIVE STUDIES; PROTEIN BINDING; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 0030020582     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050408     Document Type: Article

References (14)

1. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748
2. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisher J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44:5432
3. Fournier C, Vennin P, Hecquet B (1988) Correlation between free platinum AUC and total platinum measurement 24hr after i.v. bolus injection of cisplatin in humans. Cancer Chemother Pharmacol 21:75
4. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap K (1984) Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum II in patients with normal and impaired renal function. Cancer Res 44: 1693
5. Harland SJ, Gumbrell LA, Horwich A (1991) Carboplatin dose in combination chemotherapy for testicular cancer. Eur J Cancer 27:691
6. Horwich A, Dearnaley DP, Nicholls J, Jay G, Mason M, Harland S, Peckham MJ, Hendry WF (1991) Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 9:62
7. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520
8. Newell DR, Siddik ZH, Gumbrell LA, Boxall FE, Gore ME, Smith IE, Calvert AH (1987) Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 23:1399
9. Newell DR, Eeles RA, Gumbrell LA, Boxall FE, Horwich A, Calvert AH (1989) Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. Cancer Chemother Pharmacol 23:367
10. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503
11. Sørensen BT, Strömgren A, Jakobsen P, Jakobsen A (1991) Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 28:397
12. Sørensen BT, Strömgren A, Jakobsen P, Jakobsen A (1993) A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31:324
13. Vijgh WJF van der (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21:242
14. Warmerdam LJC van, Rodenhuis S, Tellingen O van, Maes RAA, Beijnen JH (1994) Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer Chemother Pharmacol 35:179